Cubist submits regulatory filing for Ceftolozane

|By:, SA News Editor

Cubist Pharmaceuticals (CBST -0.3%) submits its NDA for the antibiotic ceftolozane/tazobactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Last year the FDA granted the drug Fast Track status.

The company plans to file a Marketing Authorization Application with the European Medicines Agency in the second half of this year.